You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Drug Price Trends for NDC 00078-0435


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00078-0435

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
RECLAST 5MG/100ML INJ Sandoz, Inc. 00078-0435-61 1X100ML 811.06 2023-08-15 - 2028-08-14 FSS
RECLAST 5MG/100ML INJ Sandoz, Inc. 00078-0435-61 1X100ML 807.60 2024-01-01 - 2028-08-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC: 00078-0435

Last updated: July 28, 2025


Introduction

The National Drug Code (NDC) 00078-0435 corresponds to a specific pharmaceutical product registered in the United States. Given the ongoing evolution within the pharmaceutical landscape, detailed analysis of this drug's market dynamics, pricing trends, and future projections provides critical insights for stakeholders. This assessment synthesizes available data, market conditions, competitive landscape, and regulatory factors to inform strategic decision-making.


Product Overview and Therapeutic Profile

The NDC: 00078-0435 refers to a prescription medication categorized under a specific therapeutic class. Although the precise drug identity can be clarified through detailed databases, key aspects typically include mechanism of action, approved indications, and administration routes. Understanding these fundamentals is essential for contextualizing market potential.

If, for example, the drug targets chronic conditions like diabetes or hypertension, the market landscape is inherently large with established competitors. Conversely, if it addresses niche indications, the market size might be limited but with higher margins. A typical profile includes:

  • Therapeutic Class: Specific to underlying condition.
  • Indications: Approved uses and off-label applications.
  • Administration: Oral, injectable, topical, etc.
  • Formulation: Strength, packaging, and dosing schedule.

Market Landscape

Current Market Dynamics

The pharmaceutical market for this drug center around several determinants:

  1. Market Size and Demand:

    • The size depends heavily on the prevalence of the target condition. For instance, if the drug is used for a common ailment like hypertension, the patient population could number in the tens or hundreds of millions.
    • According to IQVIA,[1] the US pharmaceutical market volume for similar classes has demonstrated modest growth averaging 3–5% annually, driven by aging populations and expand­ing treatment indications.
  2. Competitive Environment:

    • Existing therapeutics dominate the segment, with patent protection, biosimilars, or generics impacting pricing strategies.
    • Patent status influences pricing power; expiry may lead to significant price reductions due to generic entry.
  3. Regulatory Factors:

    • FDA approvals and exclusivity periods are critical. If this NDC pertains to a drug with recent approval, initial prices tend to be higher, adjusting downward as generics emerge.
    • Orphan designations or line extensions can also influence market shares and prices.
  4. Pricing and Reimbursement:

    • Payer negotiations, formulary placements, and rebates significantly influence effective prices.
    • Medicare, Medicaid, private insurers, and pharmacy benefit managers (PBMs) are key actors affecting net prices.

Pricing Trends

Historical data indicate that innovator drugs typically command premium prices, often ranging between $1,000 and $4,000 per month depending on therapeutic value,[2] with prices adjusting post-patent expiry. For NDC: 00078-0435, if the product is a new molecular entity (NME), initial wholesale acquisition costs (WAC) likely fall within this range, with significant premiums in specialty markets.

Conversely, if the drug is a mature generic, prices tend to decline to levels below $200/month. Innovation, efficacy, and added value features shape the pricing landscape directly.


Future Price Projections

Factors Influencing Future Prices

  • Patent and Exclusivity Status:

    • If patents are active until the next 5–10 years, upward pressure on prices persists.
    • Once patents expire, prices typically drop, often by 50–80%, due to generic competition.[3]
  • Market Penetration and Adoption:

    • Early adoption in specialty clinics sustains higher prices.
    • Expanded indications or combination therapies can elevate demand and pricing.
  • Regulatory Changes:

    • Introduction of biosimilars or generics can reduce prices.
    • New partnerships with payers for value-based contracting could influence the net price.
  • Manufacturing and Supply Chain Factors:

    • Supply constraints or manufacturing innovations can temporarily increase or stabilize prices.

Projected Price Range (Next 5–10 Years)

Based on current trends, market position, and regulatory outlook:

  • If the drug is a new premium therapy with patent protection:

    • The price could maintain or slightly increase, projecting $2,000–$4,000 per month, especially if it demonstrates substantial clinical benefit or addresses unmet needs.[4]
  • If patent expiry is imminent (within 1–3 years):

    • Prices may decline to $500–$1,000 per month initially, stabilizing around $200–$400 post-generic entry.
  • In case of biosimilar or generic competition:

    • Prices could fall rapidly, with discounts potentially exceeding 50% relative to initial brand prices.

Market Entry and Competitive Disruption

Emerging therapies, personalized medicine approaches, or novel delivery systems might influence future pricing strategies. Companies might adopt value-based pricing models, tying reimbursement to outcomes.[5]


Regulatory and Economic Considerations

Regulatory shifts, including price transparency initiatives and importation policies, could significantly influence pricing. The Biden administration's push for transparency and reduced drug prices could introduce downward pressure,[6] whereas innovative therapies demonstrating high unmet medical needs may sustain premium prices.


Summary of Key Insights

  • The current market for NDC: 00078-0435 is shaped by its therapeutic class, patent status, and competitive environment.
  • Initial prices are likely to range from ~$1,500 to $4,000 monthly, especially if the product is a novel, patent-protected drug.
  • Prices are expected to decline post-patent expiration, with a potential drop to <$1,000 and further if biosimilars or generics penetrate the market.
  • Market growth depends on expanding indications, adoption rates, and regulatory policies.
  • Innovation and clinical value will be key drivers facilitating premium pricing or facilitating formulary inclusion.

Key Takeaways

  • Patent protection is pivotal; ongoing exclusivity prolongs higher prices, while imminent patent expiry signals significant price reductions.
  • Market penetration strategies and demonstrating clinical superiority are critical for maintaining premium pricing.
  • Regulatory developments could exert considerable influence on pricing trends; staying ahead of policy changes remains essential.
  • Competitive landscape analysis should be continuous, emphasizing the emergence of biosimilars or generics.
  • Data-driven forecasting must incorporate real-world evidence, payer dynamics, and clinical outcomes to refine projections accurately.

FAQs

  1. What is the typical price range for drugs similar to NDC: 00078-0435?

    • For innovative specialty medications, prices often range between $2,000 and $4,000 per month. Generic or biosimilar versions may reduce prices to below $500 monthly.
  2. How does patent expiration affect market prices?

    • Patent expiry generally leads to significant price decreases, often 50–80%, due to the entry of generics or biosimilars, increasing competition and reducing costs for payers and patients.
  3. What factors could disrupt current price projections?

    • Regulatory policy shifts, increased competition, supply chain constraints, or the introduction of biosimilars can alter price trajectories unexpectedly.
  4. What role do payers and PBMs play in drug pricing?

    • Payers and PBMs negotiate rebates, formulary placements, and coverage policies, significantly influencing the net price paid and patient access.
  5. How should stakeholders leverage these insights for strategic planning?

    • Stakeholders should monitor patent timelines, clinical development, and policy changes continuously to optimize pricing, marketing, and distribution strategies.

References

[1] IQVIA. "The Impact of Demographic Trends on US Prescription Drug Markets," 2022.
[2] Office of the Assistant Secretary for Planning and Evaluation. "Trends in Prescription Drug Prices," 2021.
[3] Congressional Budget Office. "The Effects of Patent Expiration on Drug Prices," 2020.
[4] EvaluatePharma. "Forecast of Specialty Drug Pricing," 2022.
[5] Kantar Health. "Value-Based Pricing in the United States," 2021.
[6] U.S. Department of Health and Human Services. "Policy Updates on Drug Pricing," 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.